Xencor, Inc. XNCR
Analyst Ratings
- Consensus
- Buy — 7 Buy · 2 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $41.11 (+7.8% upside)
Key Stats
- Today's Range
- $37.09 – $39.49
- 50-Day Range
- $21.97 – $40.60
- 52-Week Range
- $10.38 – $40.60
- Volume
- 1.18 million shs
- Average Volume
- 1.68 million shs
- Market Cap
- $3.00 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 4.45%
- Days to Cover
- 21.43
About Xencor, Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Related Stocks
Compare head-to-head: XNCR vs LLY·XNCR vs JNJ·XNCR vs ABBV·XNCR vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.